Physician profile
Stacy V Smith
NPI 1306138235
$224,722.94
in general payments reported to CMS, 2019-2025
55 companies · $33K in 2025
The $33K reported for 2025 was more than what 96% of Neuro-Ophthalmology providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $79K · 2021: $24K · 2022: $32K · 2023: $2,234 · 2024: $12K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Food and Beverage: $7,661 · Consulting Fee: $4,925 · Travel and Lodging: $4,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,500.00 |
| Food and Beverage | $7,661.03 |
| Consulting Fee | $4,925.00 |
| Travel and Lodging | $4,872.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $69,843.60 | 2019-2025 | Ajovy, Austedo Xr |
| Lilly USA, LLC | $65,041.30 | 2019-2024 | Emgality, Amyvid, Kisunla |
| Pfizer INC. | $40,817.26 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17,613.29 | 2022 | |
| Allergan, INC. | $13,256.69 | 2019-2021 | |
| Abbvie INC. | $10,718.18 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Ucb, INC. | $889.59 | 2020-2025 | Briviact, Nayzilam, Fintepla |
| Amgen INC. | $720.03 | 2019-2025 | Uplizna, Tepezza, Aimovig |
| Novartis Pharmaceuticals Corporation | $612.78 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $572.24 | 2021-2024 | Andexxa |
| Biohaven Pharmaceuticals, INC. | $438.53 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $407.00 | 2020-2024 | Ingrezza, Ongentys |
| Eisai INC. | $379.94 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $364.51 | 2019-2025 | Ultomiris |
| Sk Life Science, INC. | $242.81 | 2022-2024 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $205.15 | 2020-2025 | Vumerity, Tysabri, Avonex |
| Takeda Pharmaceuticals U.S.A., INC. | $191.43 | 2023-2024 | Hyqvia, Gammagard |
| Grifols USA, LLC | $176.47 | 2019 | |
| Eli Lilly and Company | $173.88 | 2023-2024 | Emgality |
| Genentech USA, INC. | $149.03 | 2019-2024 | Ocrevus, Ocrevus Zunovo |
| Adamas Pharmaceuticals, INC. | $122.61 | 2019-2020 | |
| Boston Scientific Corporation | $119.34 | 2023-2024 | Vercise |
| Sunovion Pharmaceuticals INC. | $117.42 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $115.51 | 2019-2021 | |
| Argenx US, INC. | $112.65 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Upsher-Smith Laboratories LLC | $95.53 | 2019-2021 | |
| Genzyme Corporation | $84.87 | 2022-2023 | |
| Penumbra, INC. | $74.22 | 2024 | Penumbra Coil 400 |
| Medtronic, INC. | $73.44 | 2024 | V-Loc 180 |
| Tg Therapeutics, INC. | $71.96 | 2024-2025 | |
| Lundbeck LLC | $70.16 | 2020-2021 | |
| Horizon Therapeutics Plc | $66.73 | 2020-2023 | Uplizna |
| Acadia Pharmaceuticals INC | $65.63 | 2024-2025 | Nuplazid |
| Zyla Life Sciences, INC. | $59.63 | 2019-2020 | |
| Abbott Laboratories | $57.98 | 2020-2023 | Infinity |
| Averitas Pharma INC. | $56.64 | 2023 | Qutenza |
| Emd Serono, INC. | $54.24 | 2023-2024 | Mavenclad |
| Supernus Pharmaceuticals, INC. | $48.59 | 2019-2020 | |
| Impel Pharmaceuticals LLC | $45.70 | 2025 | Trudhesa |
| Janssen Pharmaceuticals, INC | $40.82 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $40.72 | 2022-2023 | Trudhesa |
| Collegium Pharmaceutical, INC. | $34.71 | 2024-2025 | Xtampza |
| Sumitomo Pharma America, INC. | $29.56 | 2023 | Aptiom |
| Grt US Holding, INC. | $29.50 | 2022 | |
| Alnylam Pharmaceuticals INC. | $28.40 | 2022 | |
| Harmony Biosciences LLC | $27.56 | 2021-2022 | |
| Bausch Health US, LLC | $23.41 | 2019 | |
| Promius Pharma LLC | $23.25 | 2019 | |
| Livanova USA, INC. | $23.15 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Biotronik Nro, INC. | $19.86 | 2025 | |
| Assertio Therapeutics, INC. | $16.81 | 2020 | |
| Nevro Corp. | $16.77 | 2024 | Senza |
| Life Molecular Imaging LTD | $14.67 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.07 | 2019 | |
| Axsome Therapeutics, INC. | $13.12 | 2024 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.